A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). 

Pharmaceutical

Inversago Pharma

François Ravenelle

Annie Chevrier

Michèle Desjardins

Genevieve Gaucher

Adriana Di Marco

Karine Lalonde

Jean-Daniel Bélanger

Glenn S. Vraniak

Michael D. Harvey

Jeremy Green

Jianmin Duan

Glenn D. Crater

Inversago Pharma's CEO and Executive Team includes Michael D. Harvey and 2 others.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Inversago Pharma

Leadership Team

Board of Directors